News stories about Gemphire Therapeutics (NASDAQ:GEMP) have been trending somewhat positive this week, according to Accern. The research firm scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Gemphire Therapeutics earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.2912710816379 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Gemphire Therapeutics (GEMP) traded down $0.05 during mid-day trading on Wednesday, hitting $6.77. 67,500 shares of the company were exchanged, compared to its average volume of 135,607. Gemphire Therapeutics has a 1 year low of $6.07 and a 1 year high of $21.59. The company has a debt-to-equity ratio of 1.00, a quick ratio of 4.17 and a current ratio of 4.17. The stock has a market capitalization of $93.95, a price-to-earnings ratio of -2.00 and a beta of 3.90.
A number of brokerages have issued reports on GEMP. Zacks Investment Research raised shares of Gemphire Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 price objective for the company in a report on Thursday, November 16th. ValuEngine lowered shares of Gemphire Therapeutics from a “sell” rating to a “strong sell” rating in a report on Thursday, February 8th. Roth Capital reaffirmed a “buy” rating and set a $30.00 price objective on shares of Gemphire Therapeutics in a report on Friday, December 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $28.00 target price on shares of Gemphire Therapeutics in a report on Thursday, February 1st. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $22.75.
TRADEMARK VIOLATION WARNING: This story was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3228105/gemphire-therapeutics-gemp-receives-daily-coverage-optimism-score-of-0-17.html.
Gemphire Therapeutics Company Profile
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.